Search by Drug Name or NDC
NDC 72606-0011-01 Vegzelma 100 mg/4mL Details
Vegzelma 100 mg/4mL
Vegzelma is a INTRAVENOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by CELLTRION USA, Inc.. The primary component is BEVACIZUMAB.
MedlinePlus Drug Summary
Bevacizumab injection products are used in combination with other chemotherapy medications to treat certain types of colon and rectal cancer (cancer that begins in the large intestine), non-small cell lung cancer (NSCLC), glioblastoma (a certain type of cancerous brain tumor), renal cell cancer (RCC, a type of cancer that begins in the kidney), cervical cancer (cancer that begins in the opening of the uterus [womb]), and ovarian (female reproductive organs where eggs are formed), fallopian tube (tube that transports eggs released by the ovaries to the uterus), or peritoneal (layer of tissue that lines the abdomen) cancer. Bevacizumab (Avastin) is also used in combination with atezolizumab (Tecentriq) to treat hepatocellular carcinoma (HCC) that has spread or cannot be removed by surgery in people who have not previously received chemotherapy. Bevacizumab injection products are in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumors. This may slow the growth and spread of tumors.
Related Packages: 72606-0011-01Last Updated: 05/19/2024
MedLinePlus Full Drug Details: Bevacizumab Injection
Product Information
| NDC | 72606-0011 |
|---|---|
| Product ID | 72606-011_d58b28c8-9a47-4869-92c5-a55895ec1605 |
| Associated GPIs | |
| GCN Sequence Number | 083878 |
| GCN Sequence Number Description | bevacizumab-adcd VIAL 25 MG/ML INTRAVEN |
| HIC3 | V1X |
| HIC3 Description | ANTINEOPLAST HUM VEGF INHIBITOR RECOMB MC ANTIBODY |
| GCN | 52948 |
| HICL Sequence Number | 048357 |
| HICL Sequence Number Description | BEVACIZUMAB-ADCD |
| Brand/Generic | Brand |
| Proprietary Name | Vegzelma |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | bevacizumab-adcd |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SOLUTION |
| Route | INTRAVENOUS |
| Active Ingredient Strength | 100 |
| Active Ingredient Units | mg/4mL |
| Substance Name | BEVACIZUMAB |
| Labeler Name | CELLTRION USA, Inc. |
| Pharmaceutical Class | Vascular Endothelial Growth Factor Inhibitor [EPC], Vascular Endothelial Growth Factor Inhibitors [MoA], Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA] |
| DEA Schedule | n/a |
| Marketing Category | BLA |
| Application Number | BLA761268 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 72606-0011-01 (72606001101)
| NDC Package Code | 72606-011-01 |
|---|---|
| Billing NDC | 72606001101 |
| Package | 1 VIAL, SINGLE-USE in 1 CARTON (72606-011-01) / 4 mL in 1 VIAL, SINGLE-USE |
| Marketing Start Date | 2023-04-03 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |